There are many natural peptides with multiple N-methylamino acids that exhibit potent attractive biological activities. N-Methylation of a peptide bond(s) is also one of the standard approaches in medicinal chemistry of bioactive peptides, to improve the potency and physicochemical properties, especially membrane permeability. In this study, we investigated a facile synthesis process of N-methylated peptides via simultaneous N-methylation of several peptide bonds in the presence of peptide bonds that were not to be methylated. As a model study, we investigated the synthesis of the antiproliferative depsipeptide, IB-01212. We used a pseudoproline to protect the non-methylated peptide bond during a simultaneous N-methylation with MeI-Ag2O. Using further manipulations including a dimerization/cyclization process, IB-01212 and its derivatives were successfully synthesized. A preliminary structure-activity relationship study demonstrated that the symmetric structure contributed to the potent cytotoxic activity of IB-01212.
Introduction
A number of naturally occurring peptides with attractive biological activities contain multiple N-methylamino acids. 1 For example, cyclosporine A is an orally available immunosuppressive drug, which is currently used in the clinic. 2 Echinomycin shows antibiotic and antitumor activities by bifunctional DNA intercalation. 3 The N-methylamino acids in these nonribosomal peptides contribute to their improved membrane permeability, required for recruitment to their site of action.
N-Methylation of a peptide bond(s) is also a promising approach for improving the biological activities, metabolic stability and physicochemical properties of bioactive peptides. 1, [4] [5] [6] [7] Membrane permeability and oral bioavailability by N-methylation of multiple amide bonds in cyclic peptides have been systematically investigated. [8] [9] [10] [11] [12] [13] Although these highly N-methylated peptides could be attractive pharmaceutical resources, 14, 15 their synthesis is not straightforward in standard peptide synthesis. During the peptide elongation process, the coupling of an amino acid to the N-methylamino group is often inefficient and prone to cause racemization at the -position of activated amino acids, because of the steric hindrance. 16 In the process of the solid-phase or solution-phase synthesis of cyclosporine peptides 17, 18 and omphalotin A, 19 the coupling reactions of consecutive N-methylamino acids were optimized using various coupling reagents. An alternative approach to prepare partially N-methylated cyclic peptides was provided by the on-resin or solution-phase N-methylation strategy, in which the solvent-accessible amide NH groups were subjected to N-methylation in a regioselective manner. 10, 20 However, this approach is not suitable for synthesis of a target peptide(s), because the backbone conformations automatically determine the solvent-accessible positions for N-methylation. To overcome these problems, we designed a novel synthesis approach for N-methylated peptides via simultaneous N-methylation of all peptide bonds while protecting the non-methylated peptide bond(s).
As a synthesis target for a case study, we chose the antiproliferative depsipeptide, IB-01212 (1), which was isolated from the mycelium extract of Clonostachys sp. ESNA-A009 ( Figure 1 ). 21 IB-01212 (1) shows potent cytotoxic activity against several cancer cell lines. The C2-symmetric octapeptide 1 containing a pair of Me2Leu, Ser, MeLeu and MePhe was previously prepared via the solid-phase peptide synthesis of linear tetrapeptide 4, 22 in which the coupling reactions to the N-methylamino group were optimized using different coupling reagents ( Figure 1 ). In this article, we report a new synthesis approach for IB-01212 (1) and the structure-activity relationships of IB-01212
(1) and its derivatives.
Results and discussion

Synthesis of the linear precursor of IB-01212 via site-selective N-methylation of peptide bonds
We planned to synthesize linear precursor 4 via simultaneous N-methylation of peptide bonds while protecting a peptide bond not to be methylated of tetrapeptide 2 (Scheme 1). Among the several potential protected amide congeners, the pseudoproline dipeptide motif, Leu-Ser( Me,Me pro), which was originally designed to improve the sequence assembly by preventing the formation of a secondary structure(s), 23 was employed assuming that the non-methylated Leu-Ser peptide bond in IB-01212 (1) could be protected under simultaneous N-methylation.
The synthesis of linear substrate 4 began with the coupling of the commercially available Cbz-protected Leu-Ser( Me,Me pro) unit to Leu-Phe dipeptide 5 (Scheme 2). The resulting oxazolidine-containing peptide 6 was subjected to N-methylations under MeI-Ag2O conditions. 24 During this process, the serine -amino and -hydroxy groups were successfully protected from methylation. Removal of the Cbz group of 7 followed by additional N-methylation at the N-terminus, and deprotection by treatment with TFA provided the linear tetrapeptide 4.
With the linear tetrapeptide 4 in hand, we proceeded to investigate the one-pot dimerization/macrocyclization process for the synthesis of IB-01212 (1) according to a previous report. 22 Simultaneous dimerization and macrocyclization using MSNT 25 gave the desired IB-01212
(1) with a yield of 4.1%. The low yield was due to the concomitant production of significant amounts of unexpected cyclic monomer, trimer and epimerized dimer during this process, 22 which prompted us to investigate the stepwise route.
Synthesis of IB-01212 via stepwise ester bond formations
The considerable epimerization in the dimerization/macrocyclization process may be derived from the first ester bond formation for dimerization or the second ester bond formation for macrocyclization. To identify the problematic process causing epimerization, we investigated an alternative stepwise process for the synthesis of 1. TFA treatment of 7 followed by TBS-protection of the hydroxyl group afforded the carboxylic acid 8 (Scheme 3). On the other hand, BF3·Et2O treatment in MeOH of 7 gave the alcohol 9. The esterification reaction between 8 and 9 using MSNT in DMF yielded the octadepsipeptide 10 with a yield of 69%. In this process, no concomitant production of the epimeric products at the MePhe position was observed. After the Cbz groups of 10 were removed, N-terminal methylation followed by TFA treatment yielded the linear octapeptide 11.
MSNT-mediated macrolactonization of 11 gave the desired IB-01212 (1) with a yield of 7.5%.
However, a significant formation of an additional product with an identical mass to IB-01212 (1) was observed. To identify this additional product, the macrolactonization process from the epimeric precursor 12 at the C-terminal MePhe was investigated. The same treatment of 12 with MSNT afforded the [D-MePhe]-epimer 13 more efficiently, with a yield of 15% without the formation of 1, suggesting the cyclization from epimeric 12 is a more favorable process for providing cyclic products compared with that from 11 ( Figure 2 ). Thus, we demonstrated that the epimerization during the simultaneous dimerization and macrocyclization for the synthesis of 1 occurred at the final macrolactonization process. Of note, bis-cyclization to form the tetramers was not negligible, lowering the overall yields in both cases.
Synthesis and biological activity of IB-01212 derivatives.
Using the established synthesis approach for IB-01212 (1), a preliminary structure-activity relationship study was carried out to investigate the essential sequences for potent cytotoxicity of IB-01212 (1) . For this purpose, two IB-01212 derivatives, 14 and 15, were designed, in which the peptide sequence of the C2-symmetric component was arranged ( Figure 3 ). These two peptides were synthesized via the simultaneous N-methylation process ( Table 1) . N-methylation by treatment with excess MeI smoothly proceeded independent of the sequences, producing the expected methylated products (19 and 21).
The symmetric derivatives 14 and 15 were evaluated for cytotoxic activity against A549 cells accompanied with IB-01212 (1) and the D-MePhe epimer 13. D-MePhe epimer 13 exhibited 3.7-fold less potency compared with that of 1, suggesting that the C2-symmetric scaffold of the cyclic peptides was favorable for potent bioactivity. Peptides 14 and 15 with the arranged sequences of the identical components showed slightly less potency compared with 1, suggesting the effect of the amino acid sequences may be less significant than that of the C2-symmetry of the molecule.
Conclusions
In this study, we developed a novel synthesis approach for N-methylated peptides via simultaneous methylation of all the peptide bonds while protecting the peptide bond(s) not to be methylated. In a case study for the synthesis of the cytotoxic peptide, IB-01212 (1), a pseudoproline dipeptide component [Leu-Ser( Me,Me pro)] was employed at the Me2Leu-Ser substructure to protect from MeI-mediated multiple N-methylations. The target, IB-01212 (1), was successfully synthesized using the resulting linear precursor. We also demonstrated by a control experiment using the stepwise process that the epimerization during the one-pot dimerization/macrocyclization process of the synthesis of IB-01212 (1) occurred at the final macrolactonization step. The structure-activity relationship study on the resulting IB-01212 (1) and its derivatives suggested that the symmetric structure of IB-01212 (1) is more important for the cytotoxic activity than the amino acid sequence.
Although the pseudoproline component used in this study is applicable only for protection of the Seror Thr-containing peptide bonds, a similar approach appears to be feasible using appropriate protecting groups for the other amino acids, and this attempt is in progress.
Experimental Section
Synthesis
General Methods.
Melting points were measured by a hot stage melting point apparatus and are uncorrected. 1 H NMR spectra were recorded using a JEOL ECA-500 spectrometer. Chemical shifts are reported in δ (ppm) relative to residual peak or TMS (in CDCl3 or CD3CN) as an internal standard. 13 C NMR spectra were referenced to the residual peak as an internal standard. Chemical shifts were reported in parts per million with the residual solvent peak used as an internal standard. 1 (v/v) TFA aq. at a flow rate of 1 mL/min, and eluting products were detected by UV at 220 nm.
Preparative HPLC was performed using a COSMOSIL 5C18-ARII column (20 or 10 × 250 mm, Nacalai Tesque) with a linear gradient of CH3CN containing 0.1% (v/v) TFA aq. at a flow rate of 8 or 4 mL/min, respectively.
Cbz-Leu-Ser( Me,Me pro)-Leu-Phe-Ot-Bu (6)
To a stirred solution of H-Leu-Phe-Ot-Bu 5 26 13 
Cbz-MeLeu-Ser( Me,Me pro)-MeLeu-MePhe-Ot-Bu (7)
MeI (8.79 mL, 141 mmol) was added dropwise to a stirred suspension of 6 (2.50 g, 3.5 mmol) and Ag2O (16.3 g, 71 mmol) in dry DMF (12 mL). After being stirred in dark at room temperature overnight, the reaction was quenched with MeOH (6.85 mL, 169 mmol). The whole was extracted with EtOAc (220 mL), and the solution was washed with water and brine, and dried over Na2SO4.
Purification by flash chromatography over silica gel (n-hexane:EtOAc = 3:1) gave the compound 7 as a colorless solid ( 13 
Me 2 Leu-Ser-MeLeu-MePhe-OH (4)
Cbz-MeLeu-Ser(TBS)-MeLeu-MePhe-OH (8)
Compound 7 (540 mg, 0.72 mmol) was dissolved in TFA/H2O (95:5, 14 mL), and the solution was stirred at room temperature for 2 h. The solvent was evaporated. To the solution of the residue in dry DMF (3.2 mL) were added Et3N (0.892 mL, 6.5 mmol) and TBSCl (217 mg, 1.4 mmol) at 0 °C.
After being stirred at room temperature for 22 h, the reaction was quenched by addition of H2O (3 mL). The whole was extracted with EtOAc (70 mL), and the organic phase was washed with water, and dried over Na2SO4. Purification by flash column chromatography over silica gel (CHCl3:MeOH 13 
